Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001641172-25-026123
Filing Date
2025-09-02
Accepted
2025-09-02 06:14:17
Documents
4

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 5836
2 EX-C1 exc1.htm EX-1 104053
3 EX-C2 exc2.htm EX-2 104053
4 EX-C3 exc3.htm EX-3 104047
  Complete submission text file 0001641172-25-026123.txt   319655
Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Subject) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-80136 | Film No.: 251282845
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address NO. 28, JALAN EKOFLORA 1/13 TAMAN EKOFLORA, 81100 JOHOR BAHRU JOHOR Malaysia 00000
Business Address
Kua Khai Loon (Filed by) CIK: 0002081556 (see all company filings)

Type: SCHEDULE 13G/A